SUMMER WEBINAR SERIES

WEBINAR 3 |  Debunking Myths of New Regulations on Drug Pricing Controls
Wednesday, September 4, 2019| 12pm – 1pm EDT
Recording
Slide Deck

Objectives:
Why did the Liberal government wait until the dead of summer … when Parliament had left town and most people were on holidays … to put into effect their new regulations on prescription drug pricing? Perhaps they were hoping to avoid close scrutiny of the biased statistics and flawed analyses to justify the draconian regulated price reductions. Perhaps they hoped the patients, who would lose out on medicines NOT coming to Canada, would not notice. Perhaps they hoped the summer media would just “buy” their version of these changes.

Which is why CORD’s next Webinar, Debunking the Myths of the New Regulations on Prescription Drug Pricing Controls is a must-attend opportunity to learn more about the federal pricing regime.

We have less than a year before these new regulations come into effect. The Patented Medicine Prices Review Board (PMPRB) will soon consult on guidelines for how the new rules will operate. The fast-approaching October 21 federal election is another important opportunity to ensure our voices are heard. Join CORD and other experts to unpack the regulatory changes and how they will impact medicines available today and those yet to come.

Moderator:
Bill Dempster, CEO, 3Sixty Public Affairs

Presenters:
Neil Palmer, Senior Strategic Adviser at PDCI Market Access Inc (PDCI)
Durhane Wong-Rieger, President & CEO, CORD

WEBINAR 2 | Health Canada’s regulatory approach to drugs for rare diseases and accelerated review of human drug submissions
Thursday, July 11, 2019 | 12pm – 1pm EDT 
Recording
Slide Deck

Objectives:
Rare Disease Strategy: Health Canada approach to drug approval, access to treatments and international collaboration.
Draft Guidance: Accelerated Review of Human Drug Submissions and its applicability to approval of drugs for rare diseases with discussion of changes in process, timelines and benefits for the companies to bring rare disease drugs to Canadians.

Moderator:
Bill Dempster, CEO, 3Sixty Public Affairs

Panelists:
Fiona Frappier, Senior Policy Analyst, Office of Policy and International Collaboration, Health Canada
Megan Bettle, Director, Centre for Regulatory Excellence, Statistics and Trials, Health Canada

WEBINAR 1| Opportunities and Pitfalls in Building a National Drug List – Lessons Learned

Wednesday, June 26, 2019 | 12pm – 1pm EDT
Recording
Slide Deck 

The federal Advisory Council on the Implementation of National Pharmacare chaired by Dr. Eric Hoskins recently released its final report recommending a phased implementation of a national universal, single public payer pharmacare program. It proposes the implementation of an essential medicines list by 2022 and a comprehensive national formulary by 2027.

Moderator:
Durhane Wong-Rieger, President & CEO, Canadian Organization for Rare Disorders (CORD)

Panelists:
David Page, National Director of Health Policy, Canadian Hemophilia Society
Whitney Goulstone, Executive Director, Canadian Immunodeficiencies Patient Organization
Mina Mawani, President and CEO, Crohn’s and Colitis Canada

Will Canadians have access to the latest scientific advances and the best that modern medicine has to offer? With national pharmacare shaping up to be a key election issue, this fall’s federal election may chart the course of healthcare for generations of Canadians.

The Canadian Organization for Rare Disorders (CORD) is hosting a series of pre-election webinars to discuss key issues that will affect ALL CANADIAN PATIENTS, not just those living with a rare disorder. Unsurprisingly, a core concern for patients is timely access to medicines along with other healthcare innovations.

We invite you to join our pre-election webinar series throughout this summer to ensure that patients’ voices are heard, as the political parties and candidates shape their election promises and start campaigning for the October 21st federal election.